Primary outcome results were as follows:
length of follow-up, risperidone 17.2 months versus haloperidol 16.0 months, (p=0.6085);
monthly hospital visits, risperidone 0.023 versus haloperidol 0.084, (p=0.0040);
length of stay, risperidone 19.8 days versus haloperidol 16.64 days, (p=0.5827);
monthly physician visits, risperidone 0.441 versus haloperidol 0.244, (p=0.0005);
monthly day hospital visits, risperidone 0.03 versus haloperidol 0.003;
day hospital length of stay, risperidone 14.31 days versus haloperidol 42 days);
and total daily dose, risperidone 4.88 mg versus haloperidol 9.61mg.